iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.
iFast Diagnostics has raised $3.9M in total funding. The most recent round was Seed. The last funding was announced in May 2026.
iFast Diagnostics's investors include Future Planet Capital, Innovate UK, UK Innovation & Science Seed Fund, Raw Ventures, Meridian Health Ventures.
iFast Diagnostics is headquartered in Northampton, United Kingdom.
iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.
iFast Diagnostics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"iFast Diagnostics — Funding & Investors." VCBacked, May 27, 2026, https://www.vcbacked.co/company/ifast-diagnostics. Accessed September 30, 2026.
VCBacked. (2026). iFast Diagnostics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/ifast-diagnostics
{{cite web |title=iFast Diagnostics — Funding & Investors |url=https://www.vcbacked.co/company/ifast-diagnostics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated